Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | MYH9 | P35579 | 1/20 | 1.00 |
| ▸ | MYH10 | P35580 | 1/20 | 1.00 |
| ▸ | CASP7 | P55210 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | MYH2 | Q9UKX2 | 1/20 | 0.62 |
| ▸ | METAP2 | P50579 | 8/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438548 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL4330341 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL29354793 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL30075966 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL15919292 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL23909200 | 0.92 | MEN1 (0.85) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL23235584 | 0.92 | MEN1 (0.85) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL21067621 | 0.91 | MEN1 (0.83) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL23909209 | 0.90 | MEN1 (0.82) | MEN1KMT2AMAPTKDM4ECYP3A4 | |
| SCHEMBL23909208 | 0.90 | MEN1 (0.82) | MEN1KMT2AMAPTKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | disclosed |
| US-20240352418-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | MEGAKARYON CORPORATION (JP) | 2024-10-24 | — | — | US | disclosed |
| EP-4342982-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | Megakaryon Corporation (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-20230416686-A1 | EX VIVO PROLIFERATION OF EPITHELIAL CELLS | PROPAGENIX INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230347344-A1 | COMBINATION OF PHARMACOLOGICAL AND MICROFLUIDIC FEATURES FOR IMPROVED PLATELETS PRODUCTION | HEMOSTOD SA (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230347344-A1 | COMBINATION OF PHARMACOLOGICAL AND MICROFLUIDIC FEATURES FOR IMPROVED PLATELETS PRODUCTION | HEMOSTOD SA (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230339959-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339959-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2023-10-26 | — | — | US | disclosed |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-9492441-B2 | Drug treatment of overactive bladder | BLEBBICORP, LLC | 2016-11-15 | — | — | US | disclosed |
| US-20160030482-A1 | COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS | LONZA COLOGNE GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20160030482-A1 | COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS | LONZA COLOGNE GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030482-A1 | COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS | MYLK2, MYH2, MYO1B | MEN1 3013/4885KMT2A 2863/4885MAPT 3921/4885 |
| US-20230227452-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | MEN1 1652/4885KMT2A 3765/4885MAPT 353/4885 |
| US-20230339959-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | MYH2, MYLK2, MYO1B | MEN1 2122/4885KMT2A 3113/4885MAPT 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.